ストックスクリーナーアプリを入手
1.2301
1.59%
-0.0199
前日終値:
$1.25
開ける：
$1.22
24時間の取引高:
15,770
Relative Volume:
0.10
時価総額：
$35.47M
収益：
$40.58M
当期純損益:
$-80.65M
株価収益率:
-0.3693
EPS:
-3.331
ネットキャッシュフロー:
$-8.11M
1週間 パフォーマンス:
-3.14%
1か月 パフォーマンス:
-8.20%
6か月 パフォーマンス:
-44.59%
1年 パフォーマンス:
-26.34%
1日の値動き範囲:
$1.21
$1.25
1週間の範囲:
$1.18
$1.34
52週間の値動き範囲:
$1.01
$4.35
Celularity Inc Stock (CELU) Company Profile
Compare CELU vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.2301 | 36.05M | 40.58M | -80.65M | -8.11M | -3.331 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.36 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
732.91 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
680.20 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.00 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
281.47 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-01-30 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-06-22 | 開始されました | H.C. Wainwright | Buy |
| 2022-04-06 | ダウングレード | Truist | Buy → Hold |
| 2022-01-28 | 開始されました | Oppenheimer | Outperform |
| 2021-11-24 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Celularity Inc (CELU) 最新ニュース
Aug Summary: Can Celularity Inc maintain sales growth2026 Drop Watch & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Breakout Move: Can Celularity Inc outperform in the next rally2026 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Bond Watch: What is Celularity Inc Equity Warrants revenue forecastM&A Rumor & Weekly Momentum Picks - baoquankhu1.vn
NEXGEL to Pay $15 Million for Celularity Regenerative Biomaterial Portfolio - MyChesCo
NEXGEL signs agreement to acquire regenerative biomaterial portfolio - MSN
Stock Report: Will Celularity Inc Equity Warrant benefit from AI trends2026 Fed Impact & Precise Entry and Exit Recommendations - baoquankhu1.vn
Targets Report: Will Celularity Inc benefit from government policy2026 AllTime Highs & Long-Term Safe Investment Ideas - baoquankhu1.vn
Celularity strikes up to $35M licensing deal for biomaterials portfolio - MSN
WBB Securities Upgrades Celularity (CELU) - MSN
CelularityFinancial Details - Crunchbase
Buyback Watch: What is Celularity Inc Equity Warrants revenue forecast2026 Update & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
NEXGEL discloses $15M upfront payment for Celularity portfolio By Investing.com - Investing.com Canada
Celularity inks $35m deal for longevity push - Longevity.Technology
NXGL Stock: NEXGEL Signs Deal to Triple Revenue and Turn Profitable With Acquisition of Six Commercial-Stage Regenerative Biomaterial Products - Barchart.com
NEXGEL discloses $15M upfront payment for Celularity portfolio - Investing.com
NEXGEL Announces $15 Million Acquisition of Regenerative Biomaterial Products from Celularity, Expected to Triple Revenue and Drive Profitability - Quiver Quantitative
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities - The Manila Times
NEXGEL Inc and Celularity Inc License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products - marketscreener.com
Inside Celularity’s bet on NEXGEL to shake up wound care biomaterials - Stock Titan
Biotechnology company Celularity Inc. (NASDAQ: CELU) recently reaffirmed its strategic commercialization partnership with NEXGEL, INC. (NASDAQ: NXGL). - Bitget
Macro Review: Is Celularity Inc Equity Warrant a speculative investmentIndex Update & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Celularity licenses biomaterials portfolio for up to $35 million By Investing.com - Investing.com Canada
Celularity licenses biomaterials portfolio for up to $35 million - Investing.com Nigeria
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy - Investing News Network
Celularity Inc. Secures $35 Million Strategic License Deal and Strengthens Capital Position to Advance Longevity-Focused Strategy - marketscreener.com
NexGel Acquires Celularity Regenerative Biomaterials in Transformative Deal - TipRanks
Celularity Licenses Biomaterials Portfolio to NexGel Partner - TipRanks
NexGel to Acquire Celularity Biomaterials Assets and Exclusive License in Deal Up to $35 Million - TradingView
Deal to triple NEXGEL (NASDAQ: NXGL) revenue and add profits - Stock Titan
Celularity Sells and Licenses Biomaterials Portfolio to NexGel in Deal Worth Up to $35 Million - TradingView
Celularity (Nasdaq: CELU) monetizes biomaterials in $35M license, pivots to longevity - Stock Titan
Biotechnology company Celularity Inc. recently announced a significant personnel change. - Bitget
NEXGEL, Inc. to Acquire Regenerative Biomaterial Portfolio from Celularity, Anticipating Tripled Revenue and Immediate Profitability - Quiver Quantitative
Biotechnology company Celularity Inc. (NASDAQ: CELU) has recently reached a strategic licensing agreement totaling 35 million dollars. - Bitget
NEXGEL Signs Definitive Agreement to License and Acquire - GlobeNewswire
Celularity Inc. Announces Strategic Partnership to Commercialize Biomaterials Portfolio, Generating Up to $35 Million in Payments - Quiver Quantitative
EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue - Benzinga
NEXGEL grabs Celularity biomaterials in move expected to turn a profit - Stock Titan
Celularity names John Sprague acting CFO following executive departure - Investing.com Nigeria
CELU SEC FilingsCelularity Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Breakouts Watch: Is Celularity Inc a defensive stockPrice Action & Safe Entry Point Alerts - baoquankhu1.vn
Will Celularity Inc. stock reach all time highs in 2026Weekly Loss Report & Reliable Price Action Trade Plans - Naître et grandir
Take Profit: Is Celularity Inc Equity Warrant impacted by rising ratesJuly 2025 Price Swings & Stock Market Timing Techniques - baoquankhu1.vn
Aug Shorts: What is Celularity Inc Equity Warrants revenue forecastJuly 2025 PreEarnings & Risk Controlled Swing Alerts - baoquankhu1.vn
Celularity names John Sprague acting CFO following executive departure By Investing.com - Investing.com India
Joseph Dossantos, Acting CFO, Leaves Celularity On Feb 27, 2026SEC Filing - TradingView
Celularity Inc Announces Departure of Joseph Dossantos as Svp, Finance, Effective February 27, 2026 - marketscreener.com
Celularity Inc. Shares Seek Catalysts Amid Sector-Watch Phase () - aktiencheck.de
CELU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CELUW SEC FilingsCelularity Inc 10-K, 10-Q, 8-K Forms - Stock Titan
CELUW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Celularity Inc (CELU) 財務データ
収益
当期純利益
現金流量
EPS
1.42%
1.08%
大文字化:
|
ボリューム (24 時間):